Srinagar Magazine

IgA nephropathy Pipeline Analysis and Clinical Trials 2023: FDA Approvals, Therapies, Treatment Market and Key Companies by DelveInsight | Novartis, Jiangsu HengRui Medicine Co., Ionis Pharmaceuticals

 Breaking News
  • No posts were found

IgA nephropathy Pipeline Analysis and Clinical Trials 2023: FDA Approvals, Therapies, Treatment Market and Key Companies by DelveInsight | Novartis, Jiangsu HengRui Medicine Co., Ionis Pharmaceuticals

April 11
19:32 2023
IgA nephropathy Pipeline Analysis and Clinical Trials 2023: FDA Approvals, Therapies, Treatment Market and Key Companies by DelveInsight | Novartis, Jiangsu HengRui Medicine Co., Ionis Pharmaceuticals
IgA nephropathy Pipeline
IgA nephropathy pipeline report showcase a robust space with 30+ key companies working to develop 30+ pipeline therapies for IgA nephropathy treatment.

DelveInsight’s ‘IgA Nephropathy Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline IgA nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the IgA nephropathy pipeline domain.

 

To know more about the IgA Nephropathy Pipeline report offerings, click here @ IgA Nephropathy Pipeline Analysis

 

Key Takeaways from the IgA Nephropathy Pipeline Report

  • DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment. 
  • Leading IgA nephropathy companies working in the treatment market are Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.
  • Some of the IgA nephropathy drugs in various phases of development are BION-1301, Telitacicept, LNP023, HR19042, IONIS-FB-LRx, Atacicept, Atrasentan, AT-1501, SHR-2010, OMS721, Sibeprenlimab, Cemdisiran, Felzartamab, ADR-001, Ravulizumab, ALXN2050, APL-2, ARO-C3, Mezagitamab, Sparsentan, BCX9930, TST 004, AP 305, AP 308, DM199, KP104, ALPN-303,  and others.
  • On November 05, 2022, Vera Therapeutics, Inc. announced new clinical data presented on the Company’s two product candidates, atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplant. These data were presented in poster and oral presentations, respectively, at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, held November 3-6, 2022, in Orlando, Florida.
  • In October 2022, Transcenta Holding Limited announced that TST004, its best-in-class, humanized monoclonal antibody targeting MASP2, had received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is a key enzyme in the lectin pathway initiation of complement activation. Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation–associated thrombotic microangiopathy (HSCT-TMA). Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
  • In September 2022, Eledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the company’s Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).
  • In August 2022, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

 

IgA Nephropathy Overview

IgA nephropathy, also known as Berger’s disease, is a kidney disease in which IgA deposits accumulate in the kidneys, causing inflammation and damage to kidney tissues. IgA is an antibody, which is a protein produced by the immune system to defend the body against foreign substances such as bacteria or viruses. The IgA nephropathy causes are not known. 

Hematuria and proteinuria, ankle swelling, and high blood pressure are the most common IgA nephropathy symptoms. Some of the procedures used for IgA nephropathy diagnosis include urine tests, blood tests, Glomerular Filtration rate, and kidney biopsy. There is no cure for IgA nephropathy, but treatments can help prevent further kidney damage.

 

Request for a sample report @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

IgA Nephropathy Pipeline Drugs mentioned in the report:

  • Sparsentan: Travere Therapeutics
  • Atrasentan: Chinook Therapeutics
  • LNP023: Novartis Pharmaceuticals
  • HR19042: Jiangsu HengRui Medicine Co., Ltd.
  • ADR-001: Rohto Pharmaceutical Co., Ltd.
  • And Many Others

 

Learn more about the IgA nephropathy clinical trials advancements @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

IgA Nephropathy Therapeutics Assessment

The IgA nephropathy pipeline report proffers an integral view of IgA nephropathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the IgA Nephropathy Pipeline Report 

  • Coverage: Global 
  • IgA Nephropathy Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • IgA Nephropathy Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • IgA Nephropathy Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
  • IgA Nephropathy Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
  • IgA Nephropathy Therapeutics Assessment By Mechanism of Action: Endothelin A receptor antagonists, Angiotensin type 1 receptor antagonists, Bacteria replacements, Gastrointestinal microbiome modulators, Opioid kappa receptor antagonists, Opioid mu receptor agonists, Serotonin 3 receptor antagonists
  • Key IgA Nephropathy Companies: Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.
  • Key IgA Nephropathy Pipeline Therapies: BION-1301, Telitacicept, LNP023, HR19042, IONIS-FB-LRx, Atacicept, Atrasentan, AT-1501, SHR-2010, OMS721, Sibeprenlimab, Cemdisiran, Felzartamab, ADR-001, Ravulizumab, ALXN2050, APL-2, ARO-C3, Mezagitamab, Sparsentan, BCX9930, TST 004, AP 305, AP 308, DM199, KP104, ALPN-303, and others.

 

Dive deep into rich insights for new drugs for IgA nephropathy treatment; visit @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

Table of Contents

1. IgA Nephropathy Pipeline Report Introduction

2. IgA Nephropathy Pipeline Report Executive Summary

3. IgA Nephropathy Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. IgA Nephropathy Clinical Trial Therapeutics

6. IgA Nephropathy Pipeline: Late Stage Products (Pre-registration)

7. IgA Nephropathy Pipeline: Late Stage Products (Phase III)

8. IgA Nephropathy Pipeline: Mid Stage Products (Phase II)

9. IgA Nephropathy Pipeline: Early Stage Products (Phase I)

10. IgA Nephropathy Pipeline Therapeutics Assessment

11. Inactive Products in the IgA Nephropathy Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key IgA Nephropathy Companies

14. Key Products in the IgA Nephropathy Pipeline

15. IgA Nephropathy Unmet Needs

16. IgA Nephropathy Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

For further information on the IgA nephropathy pipeline therapeutics, reach out @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting